Physician profile
Dawn Bishop
NPI 1467932889
$1,526.00
in general payments reported to CMS, 2019-2025
12 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.84 · 2022: $460 · 2023: $95.05 · 2024: $544 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $284.82 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $232.90 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $221.86 | 2024 | Nuplazid |
| Novo Nordisk INC | $143.18 | 2022-2025 | Wegovy |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Esperion Therapeutics, INC. | $124.16 | 2022 | |
| Sage Therapeutics, LLC | $100.28 | 2025 | |
| Incyte Corporation | $95.71 | 2022 | |
| Gilead Sciences, INC. | $95.05 | 2023 | Epclusa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.84 | 2021 | |
| Alpha Cognition USA, INC. | $33.49 | 2025 | Zunveyl |
| Otsuka America Pharmaceutical, INC. | $18.71 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.